Clinical trial
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients…
NCT00039234 · Maxim Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00039234 |
|---|---|
| Title | Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver |
| Official title | A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis |
| Lead sponsor | Maxim Pharmaceuticals, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma (Skin), Metastatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, histamine dihydrochloride |
| Start date | Sep 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | Canada, Germany, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: